Madrigal Pharmaceuticals

Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
3 Biotechs Compete for the Same $108-Billion-Dollar Market
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Flag link:
Unpartnered assets: on the shelf or hidden treasure?
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Flag link:
3 Biotechs That Might Get Bought Out in 2023
3 Biotechs That Might Get Bought Out in 2023
Motley Fool
M&A
Madrigal Pharmaceuticals
Amylyx
Aurinia Pharmaceuticals
Flag link:
89Bio Enlivened by Nash success
89Bio Enlivened by Nash success
EP Vantage
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Big caps bounce back for biopharma
Big caps bounce back for biopharma
EP Vantage
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Flag link:
Madrigal shares triple on positive NASH study results
Madrigal shares triple on positive NASH study results
BioPharma Dive
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
Flag link:
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Flag link:
A NASH player touts positive PhIII data, but true test still lies ahead
A NASH player touts positive PhIII data, but true test still lies ahead
Endpoints
NASH
clinical trials
Madrigal Pharmaceuticals
resmetirom
NAFLD
Flag link:
3 Biotech Stocks With Major Catalysts in January
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom
Flag link:
Biopharma developments over the Christmas period
Biopharma developments over the Christmas period
EP Vantage
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Flag link:
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Motley Fool
liver disease
NASH
The Liver Meeting
Assembly Biosciences
CymaBay Therapeutics
Madrigal Pharmaceuticals
Flag link:
NASH drugmaker stocks rebound after dip on FDA guidance
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit
Flag link:
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
Motley Fool
TG Therapeutics
Madrigal Pharmaceuticals
Puma Biotechnology
Flag link:
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Motley Fool
Madrigal Pharmaceuticals
NASH
MGL-3196
Viking Therapeutics
VK2809
Flag link:
The 4 Best Biotech Stocks of 2018 (So Far)
The 4 Best Biotech Stocks of 2018 (So Far)
Motley Fool
biotech
Arrowhead Research
Endocyte
Arqule
Madrigal Pharmaceuticals
Flag link:
3 Huge Biotech Winners in 2018 (So Far)
3 Huge Biotech Winners in 2018 (So Far)
Motley Fool
biotech
Arrowhead Pharmaceuticals
Endocyte
Madrigal Pharmaceuticals
Flag link:

Pages